NHS to Offer Weight-Loss Jab Wegovy for Heart Attack and Stroke Prevention
More than a million individuals in England at elevated risk of heart attacks and strokes are set to receive the weight-loss jab, Wegovy, via the NHS. The National Institute for Health and Care Excellence (NICE) has endorsed the weekly injection for those with pre-existing heart conditions, stroke history, or serious peripheral arterial disease who are also overweight.
Enhanced Protection Against Cardiovascular Events
This initiative aims to provide an 'extra layer of protection' for eligible patients already managing their heart health with other medicines, such as statins, and adhering to a healthy diet. Clinical trials have demonstrated a compelling link between Wegovy, also known as semaglutide, and a significant reduction in the risk of future cardiovascular events.
Studies involving tens of thousands of participants revealed a 20% reduced risk of heart attacks and strokes when the jab was administered alongside existing heart medications. Crucially, these benefits were observed early in the trials, suggesting the drug exerts direct effects on the heart and blood vessels, independent of substantial weight loss.
Eligibility and Administration
Patients with a Body Mass Index (BMI) of 27 or higher, classifying them as overweight or obese, will be considered. A GP or specialist will determine suitability. Those prescribed Wegovy will be able to self-administer the medication at home using a pen injector device. The rollout is anticipated to commence this summer.
Wegovy functions by mimicking the GLP-1 hormone, which promotes feelings of fullness and slows digestion, thereby aiding weight loss. While side effects such as bloating, nausea, or discomfort may occur, doctors will also emphasise lifestyle modifications, including healthy eating and regular exercise, to sustain weight management.
Currently, NHS treatment with Wegovy is limited to two years, with ongoing research into its long-term effects. NICE has confirmed an agreement with pharmaceutical company Novo Nordisk to ensure the treatment is cost-effective for the NHS.
